治疗复发或难治性外周T细胞淋巴瘤的新型药物
Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
作者信息
Marchi Enrica, Raufi Alexander G, O'Connor Owen A
机构信息
Columbia University Medical Center, Center for Lymphoid Malignancies, 51 West 51st Street, Suite 200, New York, NY 10019, USA.
Columbia University Medical Center, Center for Lymphoid Malignancies, 51 West 51st Street, Suite 200, New York, NY 10019, USA.
出版信息
Hematol Oncol Clin North Am. 2017 Apr;31(2):359-375. doi: 10.1016/j.hoc.2016.11.002.
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell malignancies associated with exceptionally poor prognoses. Currently, chemotherapy remains the standard of care, but outcomes are suboptimal, with 5-year survival rates ranging from 15% to 25%. In recent years, several novel agents, including pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have been approved for the treatment of relapsed/refractory PTCL. In addition, numerous other therapies with different mechanisms of action and targets are currently under investigation. This article discusses in detail agents currently available, those currently under investigation, and active combination trials.
外周T细胞淋巴瘤（PTCL）是一组异质性的成熟T细胞恶性肿瘤，预后极差。目前，化疗仍然是标准治疗方法，但治疗效果并不理想，5年生存率在15%至25%之间。近年来，几种新型药物，包括普拉曲沙、罗米地辛、贝利司他和本妥昔单抗，已被批准用于治疗复发/难治性PTCL。此外，目前还有许多其他作用机制和靶点不同的疗法正在研究中。本文详细讨论了目前可用的药物、正在研究的药物以及正在进行的积极联合试验。
Zotero 插件